拮抗IL-17A可减轻银屑病小鼠模型的皮肤炎症和血管功能障碍
研究在三种银屑病样小鼠模型中分析血管功能与炎症,发现血管功能障碍与外周IL-17A水平和主动脉壁中性粒细胞浸润相关;成功的抗IL-17A治疗可降低外周氧化应激、促炎细胞因子和血管炎症,提示抗IL-17A治疗可能有助于减轻和预防银屑病患者的血管疾病。
要点
- 血管功能障碍与银屑病样皮肤病变严重程度、外周IL-17A水平及主动脉壁中性粒细胞浸润相关。
- 成功抗IL-17A治疗银屑病样皮损可降低外周氧化应激、促炎细胞因子和血管炎症。
- 作者认为抗IL-17A治疗可能代表减轻和预防银屑病患者血管疾病的有用方法。
核心结论
- 数据强调IL-17A在连接银屑病皮肤病变与血管疾病中的核心作用。
- 作者认为抗IL-17A治疗可能代表减轻和预防银屑病患者血管疾病的有用方法。
研究设计与样本
- 研究分析三种银屑病样皮肤病严重程度不同的小鼠模型的血管功能和炎症。
- 模型一为K14-IL-17Aind/+小鼠,角质形成细胞特异性过表达IL-17A,早发严重银屑病样表型。
- 模型二为纯合CD11c-IL-17Aind/ind和杂合CD11c-IL-17Aind/+小鼠,在CD11c+细胞过表达IL-17A,迟发中度银屑病样皮肤病。
- 模型三为咪喹莫特诱导的急性银屑病样皮肤炎症模型。
主要发现
- 血管功能障碍与银屑病样皮肤病严重程度相似,并与外周IL-17A水平和中性粒细胞浸润主动脉血管壁相关。
- 成功抗IL-17A治疗银屑病样皮损可降低外周氧化应激水平、促炎细胞因子和血管炎症。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Besides skin inflammation, patients with severe psoriasis suffer from an increased risk of cardiovascular mortality. IL-17A plays a central role in the development of psoriasis and might connect skin and vascular disease. The aim of this study was to clarify whether anti-IL-17A therapy could also ameliorate the vascular dysfunction associated with severe psoriasis. We analyzed three murine models with varying severities of psoriasis-like skin disease concerning their vascular function and inflammation: (i) K14-IL-17Aind/+ mice with keratinocyte-specific IL-17A overexpression and an early-onset severe psoriasis-like phenotype; (ii) homozygous CD11c-IL-17Aind/ind and heterozygous CD11c-IL-17Aind/+ mice overexpressing IL-17A in CD11c+ cells, leading to a delayed onset of moderate psoriasis-like skin disease; and (iii) the acute model of imiquimod-induced psoriasis-like skin inflammation. Similar to the severity of skin disease, vascular dysfunction correlated with peripheral IL-17A levels and neutrophil infiltration into the aortic vessel wall. Successful anti-IL-17A treatment of psoriatic skin lesions diminished peripheral oxidative stress levels, proinflammatory cytokines, and vascular inflammation. These data highlight the pivotal role of IL-17A linking the development of skin lesions and vascular disease in psoriasis. Anti-IL-17A therapy might thus represent a useful approach to attenuate and prevent vascular disease in psoriasis patients.
引用
- Schüler R, Brand A, Klebow S, et al. Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis. J Invest Dermatol. 2018. PMID: 30367871. doi:10.1016/j.jid.2018.09.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。